RESILIA tissue valves combine a proven design with advanced technology, designed to promote long-term patient benefit and ease of use for physicians. Since 2017, more than 150,000 INSPIRIS RESILIA valves have been implanted worldwide; for patients, this means a life of lasting benefit.*
In this special issue of Inspire, we bring you the latest science on RESILIA tissue presented at the European Association of Cardio-Thoracic Surgery 2022 annual meeting in Milan, Italy.
Discover more on RESILIA tissue through the current and past issues below.
This healthcare professional focused booklet explores the latest clinical studies and publications involving the INSPIRIS RESILIA valve and RESILIA tissue through the review of 24 publications and abstracts.
Each reference has been summarized visually over 1 or 2 slides, for you to save time.
*No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.
†RESILIA tissue tested against tissue from commercially-available bovine pericardial valves from Edwards in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg 2015;149:340–5
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
An educational website focused on TAVI is underway
Thank you. We will keep you updated when new content is available.